Michael S. Weiss
About Michael S. Weiss
Michael S. Weiss is the Executive Vice Chairman of Strategic Development with a J.D. from Columbia Law School and a B.S. in Finance from the University at Albany. He has held key leadership roles in several biopharmaceutical companies, including TG Therapeutics, Mustang Bio, and Checkpoint Therapeutics.
Company
Michael S. Weiss is currently the Executive Chairman, Chief Executive Officer, and President of TG Therapeutics, Inc. He has been with TG Therapeutics, Inc. since December 2011, serving in multiple capacities. He also serves as the Executive Chairman of the Board of Directors of Mustang Bio, Inc., and as the Chairman of the Board of Directors of Checkpoint Therapeutics, Inc. Previously, he founded Access Oncology in 1999, which was later acquired by Keryx Biopharmaceuticals in 2004, where he remained as the Chief Executive Officer following the merger.
Title
Michael S. Weiss holds the title of Executive Vice Chairman, Strategic Development. In his current role, he focuses on the strategic growth and development of TG Therapeutics, Inc. In addition to his primary title, he serves as Executive Chairman of the Board of Directors of Mustang Bio, Inc., and Chairman of the Board of Directors of Checkpoint Therapeutics, Inc.
Education and Expertise
Michael S. Weiss earned a Bachelor of Science in Finance from the University at Albany, providing him with a strong foundation in financial principles. He furthered his education with a Juris Doctor degree from Columbia Law School. His educational background in both law and finance has equipped him with the expertise necessary for his various leadership roles in the pharmaceutical and biotechnology sectors.
Background
Michael S. Weiss began his professional career as a lawyer with Cravath, Swaine & Moore LLP, one of the most prestigious law firms in the United States. In 1999, he founded Access Oncology, a company focused on the development and commercialization of oncology therapies. Access Oncology was acquired by Keryx Biopharmaceuticals in 2004, and Weiss served as the Chief Executive Officer of Keryx following the merger. His extensive experience in both legal and executive roles has established him as a seasoned leader in the biopharmaceutical industry.
Achievements
Michael S. Weiss has achieved significant milestones in his career. He successfully founded Access Oncology and oversaw its acquisition by Keryx Biopharmaceuticals in 2004, subsequently becoming the CEO of Keryx. At TG Therapeutics, Inc., where he has been serving since December 2011, Weiss has taken on multiple leadership roles, including Executive Chairman, Chief Executive Officer, and President. His leadership roles extend to Mustang Bio, Inc., and Checkpoint Therapeutics, Inc., where he serves as Executive Chairman and Chairman of the Board of Directors, respectively.